BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BIOGEN INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$233.48+0.83 (+0.36%)
Close on Oct 19, 2026
- Market cap
- $34.72B
- P/E (TTM)
- 41.3
- Dividend yield
- –
BIOGEN INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $7.18B | $7.15B | $7.12B | $7.28B | $7.21B | $7.23B | $7.21B | $7.21B | $7.25B | $7.20B | $7.25B | $7.32B | 71.6% | -0.3% |
| MS Product Revenues | $3.90B | $4.04B | $4.04B | $4.19B | $4.18B | $4.23B | $4.35B | $4.45B | $4.55B | $4.61B | $4.66B | $4.76B | 38.9% | -6.8% |
| Rare Disease Product Revenue | $2.21B | $2.15B | $2.15B | $2.17B | $2.14B | $2.13B | $1.99B | $1.92B | $1.88B | $1.78B | $1.80B | – | 22.0% | +3.3% |
| TYSABRI | $1.72B | $1.73B | $1.67B | $1.68B | $1.66B | $1.67B | $1.72B | $1.76B | $1.81B | $1.84B | $1.88B | $1.90B | 17.2% | +3.9% |
| SPINRAZA | $1.51B | $1.50B | $1.55B | $1.61B | $1.62B | $1.66B | $1.57B | $1.56B | $1.63B | $1.64B | $1.74B | $1.79B | 15.0% | -7.0% |
| Royalty Attributed To OCREVUS | $1.47B | $1.44B | $1.41B | $1.38B | $1.34B | $1.33B | $1.34B | $1.32B | $1.30B | $1.29B | $1.27B | $1.24B | 14.7% | +9.5% |
| Fumarate | $1.25B | $1.37B | $1.43B | $1.54B | $1.55B | $1.56B | $1.60B | $1.59B | $1.61B | $1.59B | $1.59B | $1.64B | 12.5% | -19.0% |
| Interferon | $925.20M | $946.80M | $945.60M | $955.90M | $946.50M | $950.70M | $968.00M | $1.01B | $1.05B | $1.10B | $1.11B | $1.14B | 9.2% | -2.3% |
| VUMERITY | $771.20M | $787.00M | $746.80M | $742.30M | $685.80M | $639.30M | $628.00M | $607.80M | $615.20M | $595.60M | $576.30M | $570.70M | 7.7% | +12.5% |
| Biosimilars | $701.60M | $730.50M | $729.10M | $760.80M | $760.60M | $777.00M | $793.10M | $779.80M | $777.50M | $774.50M | $770.00M | $756.60M | 7.0% | -7.8% |
| AVONEX | $684.20M | $691.90M | $695.50M | $703.00M | $690.70M | $695.80M | $707.50M | $743.60M | $779.60M | $817.10M | $811.00M | $835.00M | 6.8% | -0.9% |
| Contract manufacturing revenue | $641.70M | $634.30M | $679.40M | $766.80M | $847.20M | $722.20M | $592.10M | $579.40M | $610.40M | $693.50M | $848.20M | $917.70M | 6.4% | -24.3% |
| SKYCLARYS | $584.90M | $547.30M | $520.50M | $489.30M | $458.70M | $428.40M | $382.50M | $336.20M | $233.90M | $133.90M | $55.90M | – | 5.8% | +27.5% |
| TECFIDERA | $480.40M | $583.10M | $679.70M | $795.70M | $860.30M | $918.90M | $967.10M | $983.60M | $990.30M | $992.30M | $1.01B | $1.07B | 4.8% | -44.2% |
| BENEPALI | $458.70M | $464.00M | $453.20M | $470.30M | $466.50M | $471.70M | $479.10M | $461.90M | $456.60M | $448.50M | $438.80M | $431.30M | 4.6% | -1.7% |
| ZURZUVAE | $247.20M | $222.80M | $195.10M | $152.30M | $119.00M | $87.50M | $72.20M | $50.90M | $28.90M | $14.00M | $1.60M | – | 2.5% | +107.7% |
| PLEGRIDY | $241.00M | $254.90M | $250.10M | $252.90M | $255.80M | $254.90M | $260.50M | $268.40M | $272.60M | $286.60M | $294.70M | $300.30M | 2.4% | -5.8% |
| Alzheimer's Collaboration | $213.00M | $204.20M | $177.70M | $157.30M | $133.20M | $90.10M | $59.90M | – | – | – | – | – | 2.1% | +59.9% |
| IMRALDI | $183.50M | $192.40M | $190.20M | $197.70M | $199.20M | $205.70M | $213.10M | $216.60M | $216.90M | $222.50M | $222.10M | $219.70M | 1.8% | -7.9% |
| QALSODY | $115.80M | $103.90M | $86.90M | $73.60M | $58.30M | $43.30M | $32.40M | $24.00M | $14.60M | $10.50M | $5.90M | – | 1.2% | +98.6% |
| FLIXABI | $43.80M | $50.00M | $52.60M | $58.80M | $59.70M | $58.50M | $63.20M | $63.80M | $67.80M | $74.80M | $77.40M | $80.00M | 0.4% | -26.6% |
| Royalty and other revenue | $42.60M | $52.20M | $53.50M | $52.50M | $52.50M | $41.90M | $60.50M | $61.10M | $102.70M | $87.40M | $51.10M | $55.10M | 0.4% | -18.9% |
| BYOOVIZ | $15.00M | $23.50M | $32.40M | $33.80M | $34.80M | $39.90M | $36.60M | $36.50M | $35.40M | $28.70M | $31.70M | $25.60M | 0.1% | -56.9% |
| FAMPYRA | $1.10M | $1.10M | $1.40M | $14.70M | $34.10M | $52.80M | $71.70M | $80.30M | $80.90M | $85.60M | $90.50M | $90.40M | 0.0% | -96.8% |
| TOFIDENCE | $600.00K | $600.00K | $700.00K | $200.00K | $400.00K | $1.20M | $1.10M | $1.00M | $800.00K | $0 | $0 | – | 0.0% | +50.0% |
| FUMADERM And ADUHELM | $0 | $400.00K | $2.10M | $4.80M | $6.90M | $9.20M | $10.30M | $10.00M | $9.90M | $10.60M | $10.20M | $9.90M | 0.0% | -100.0% |
| Revenue from anti-CD20 therapeutic programs | – | – | – | – | – | – | – | – | – | – | – | $1.70B | – | – |
| Contract manufacturing, royalty and other revenue | – | – | – | – | – | – | – | – | – | – | – | $972.80M | – | – |
By region
From the segment and revenue-disaggregation notes of Biogen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.